149 related articles for article (PubMed ID: 38315194)
1. Component prediction in combined hepatocellular carcinoma-cholangiocarcinoma: habitat imaging and its biologic underpinnings.
Xiao Y; Huang P; Zhang Y; Lu X; Zhou C; Wu F; Wang Y; Zeng M; Yang C
Abdom Radiol (NY); 2024 Apr; 49(4):1063-1073. PubMed ID: 38315194
[TBL] [Abstract][Full Text] [Related]
2. Combined hepatocellular carcinoma-cholangiocarcinoma with a predominant HCC component: better survival and MRI-based prediction.
Xiao Y; Zheng X; Zhou C; Huang P; Wu F; Yang C; Zeng M
Eur Radiol; 2023 Feb; 33(2):1412-1421. PubMed ID: 36112193
[TBL] [Abstract][Full Text] [Related]
3. How to utilize LR-M features of the LI-RADS to improve the diagnosis of combined hepatocellular-cholangiocarcinoma on gadoxetate-enhanced MRI?
Lee HS; Kim MJ; An C
Eur Radiol; 2019 May; 29(5):2408-2416. PubMed ID: 30552477
[TBL] [Abstract][Full Text] [Related]
4. Combined hepatocellular-cholangiocarcinoma: which preoperative clinical data and conventional MRI characteristics have value for the prediction of microvascular invasion and clinical significance?
Wang X; Wang W; Ma X; Lu X; Li S; Zeng M; Xu K; Yang C
Eur Radiol; 2020 Oct; 30(10):5337-5347. PubMed ID: 32385649
[TBL] [Abstract][Full Text] [Related]
5. Revealing the role of necroptosis microenvironment: FCGBP + tumor-associated macrophages drive primary liver cancer differentiation towards cHCC-CCA or iCCA.
Wang C; Chen C; Hu W; Tao L; Chen J
Apoptosis; 2024 Apr; 29(3-4):460-481. PubMed ID: 38017206
[TBL] [Abstract][Full Text] [Related]
6. Combined Hepatocellular-Cholangiocarcinoma: Magnetic Resonance Imaging Features and Prognosis According to Risk Factors for Hepatocellular Carcinoma.
Kim DH; Choi SH; Kim DW; Lee SS; Lim YS; Kim SY; Kim HJ; Kim JH; Byun JH
J Magn Reson Imaging; 2021 Jun; 53(6):1803-1812. PubMed ID: 33565208
[TBL] [Abstract][Full Text] [Related]
7. Risk stratification of LI-RADS M and LI-RADS 4/5 combined hepatocellular cholangiocarcinoma: prognostic values of MR imaging features and clinicopathological factors.
Wang Y; Zhu GQ; Zhou CW; Li N; Yang C; Zeng MS
Eur Radiol; 2022 Aug; 32(8):5166-5178. PubMed ID: 35316365
[TBL] [Abstract][Full Text] [Related]
8. Combining imaging and tumour biopsy improves the diagnosis of combined hepatocellular-cholangiocarcinoma.
Gigante E; Ronot M; Bertin C; Ciolina M; Bouattour M; Dondero F; Cauchy F; Soubrane O; Vilgrain V; Paradis V
Liver Int; 2019 Dec; 39(12):2386-2396. PubMed ID: 31544304
[TBL] [Abstract][Full Text] [Related]
9. Histopathological components correlated with MRI features and prognosis in combined hepatocellular carcinoma-cholangiocarcinoma.
Zhou C; Lu X; Wang Y; Qian X; Yang C; Zeng M
Eur Radiol; 2022 Oct; 32(10):6702-6711. PubMed ID: 35976399
[TBL] [Abstract][Full Text] [Related]
10. Component with abundant immune-related cells in combined hepatocellular cholangiocarcinoma identified by cluster analysis.
Yagi N; Suzuki T; Mizuno S; Kojima M; Kudo M; Sugimoto M; Kobayashi S; Gotohda N; Ishii G; Nakatsura T
Cancer Sci; 2022 May; 113(5):1564-1574. PubMed ID: 35226764
[TBL] [Abstract][Full Text] [Related]
11. Major and ancillary features according to LI-RADS in the assessment of combined hepatocellular-cholangiocarcinoma.
Granata V; Fusco R; Venanzio Setola S; Sandomenico F; Luisa Barretta M; Belli A; Palaia R; Tatangelo F; Grassi R; Izzo F; Petrillo A
Radiol Oncol; 2020 May; 54(2):149-158. PubMed ID: 32463393
[TBL] [Abstract][Full Text] [Related]
12. DCE-MRI based radiomics nomogram for preoperatively differentiating combined hepatocellular-cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma.
Zhou Y; Zhou G; Zhang J; Xu C; Zhu F; Xu P
Eur Radiol; 2022 Jul; 32(7):5004-5015. PubMed ID: 35128572
[TBL] [Abstract][Full Text] [Related]
13. Differentiation of hepatocellular carcinoma from intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in high-risk patients matched to MR field strength: diagnostic performance of LI-RADS version 2018.
Zou X; Luo Y; Morelli JN; Hu X; Shen Y; Hu D
Abdom Radiol (NY); 2021 Jul; 46(7):3168-3178. PubMed ID: 33660040
[TBL] [Abstract][Full Text] [Related]
14. Preoperative evaluation of MRI features and inflammatory biomarkers in predicting microvascular invasion of combined hepatocellular cholangiocarcinoma.
Zhang J; Dong W; Liu W; Fu J; Liao T; Li Y; Huo L; Jia N
Abdom Radiol (NY); 2024 Mar; 49(3):710-721. PubMed ID: 38112787
[TBL] [Abstract][Full Text] [Related]
15. Combined hepatocellular-cholangiocarcinoma: can we use contrast-enhanced ultrasound Liver Imaging Reporting and Data System (LI-RADS) to predict the patient's survival?
Yang J; Huang JY; Chen X; Ling WW; Luo Y; Shi YJ; Liu JB; Lu Q; Lyshchik A
Eur Radiol; 2021 Aug; 31(8):6397-6405. PubMed ID: 33492470
[TBL] [Abstract][Full Text] [Related]
16. Comparing the clinicopathological characteristics of combined hepatocellular-cholangiocarcinoma with those of other primary liver cancers by use of the updated World Health Organization classification.
Yen CC; Yen CJ; Shan YS; Lin YJ; Liu IT; Huang HY; Yeh MM; Chan SH; Tsai HW
Histopathology; 2021 Oct; 79(4):556-572. PubMed ID: 33837585
[TBL] [Abstract][Full Text] [Related]
17. Imaging features of combined hepatocellular and cholangiocarcinoma compared with those of hepatocellular carcinoma and intrahepatic cholangiocellular carcinoma in a Chinese population.
Wang Y; Yang Q; Li S; Luo R; Mao S; Shen J
Clin Radiol; 2019 May; 74(5):407.e1-407.e10. PubMed ID: 30799097
[TBL] [Abstract][Full Text] [Related]
18. MRI features of combined hepatocellular- cholangiocarcinoma versus mass forming intrahepatic cholangiocarcinoma.
Sammon J; Fischer S; Menezes R; Hosseini-Nik H; Lewis S; Taouli B; Jhaveri K
Cancer Imaging; 2018 Feb; 18(1):8. PubMed ID: 29486800
[TBL] [Abstract][Full Text] [Related]
19. The significance of the predominant component in combined hepatocellular-cholangiocarcinoma: MRI manifestation and prognostic value.
Sheng R; Yang C; Zhang Y; Wang H; Zheng B; Han J; Sun W; Zeng M
Radiol Med; 2023 Sep; 128(9):1047-1060. PubMed ID: 37474663
[TBL] [Abstract][Full Text] [Related]
20. Can contrast enhanced ultrasound differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma?
Huang JY; Li JW; Ling WW; Li T; Luo Y; Liu JB; Lu Q
World J Gastroenterol; 2020 Jul; 26(27):3938-3951. PubMed ID: 32774068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
